Vanta Bioscience P/E Ratio
Current P/E Ratio
169.0
High Valuation
Very High - High growth expectations or significantly overvalued
Vanta Bioscience (VANTABIO) P/E ratio is 169.0 (High), EPS (TTM) ₹0.15, current price ₹ on None — Very High - High growth expectations or significantly overvalued. For live price, revenue and the complete fundamental profile, see VANTABIO share price screener.
Current Valuation Metrics
P/E Ratio
169.0
Current Price
₹
EPS (TTM)
₹0.15
Exchange
None
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
54.16
Sector Median
30.68
Sector Rank
#11 of 194
Sector Percentile
5.7%
Earnings Breakdown (TTM)
TTM EPS
₹-3.95
Mar 2022
₹0.11
Dec 2022
₹-4.06
VANTABIO P/E Ratio — Valuation Signal & Historical Context
Vanta Bioscience P/E 169.0 — signal: Overvalued. Browse VANTABIO complete financial statements for revenue, profit, balance sheet and cash flow data.
- Stock appears overvalued with PE of 169.0, suggesting caution for new investments
- Trading at premium to sector average PE of 54.16
VANTABIO vs Healthcare Peers — P/E Ratio Comparison
Vanta Bioscience P/E 169.0 vs Healthcare average 54.16, median 30.68 — range 2.86–879.0.
Sector Average
54.16
Sector Median
30.68
Lowest P/E
2.86
Highest P/E
879.0
Companies
194
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Sunrest Lifescience | SUNREST | 3.5 | ₹30 | Low |
| Phaarmasia | PHRMASI | 4.06 | ₹68 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.97 | ₹7,724 | Low |
| Shelter Pharma | SHELTER | 5.34 | ₹49 | Low |
| Mono Pharmacare | MONOPHARMA | 6.25 | ₹20 | Low |
| Zenith Drugs | ZENITHDRUG | 7.69 | ₹77 | Low |
| Amwill Health Care | AMWILL | 7.81 | ₹89 | Low |
| Brooks Laboratories | BROOKS | 8.06 | ₹206 | Low |
| Royal Sense | ROYAL | 8.24 | ₹59 | Low |